Solanezumab

• CAT Number: I042404
• CAS Number: 955085-14-0
• Molecular Weight: 144.1 (kDa)
• Purity: ≥95%

Solanezumab (Cat No.: I042404) is a humanized monoclonal antibody that targets soluble monomeric amyloid-beta (Aβ) peptides, implicated in the pathogenesis of Alzheimer’s disease. By binding to Aβ, Solanezumab facilitates its clearance from the brain, potentially reducing amyloid plaque formation and associated neurotoxicity. It was developed to slow cognitive decline in early-stage Alzheimer’s patients. Although clinical trials showed limited efficacy in modifying disease progression, Solanezumab remains an important tool in Alzheimer’s research, contributing to the understanding of amyloid-targeting strategies in neurodegenerative therapy.

Reference

[1]. [1]Honig LS, et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease. N Engl J Med. 2018 Jan 25;378(4):321-330.
[Content Brief]